Clinical Trials Browser

darolutamide × Tumor-Agnostic × 90 days × Clear all

NCT04464226 2026-04-15

Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer

Phase 3 Active not recruiting

Neoplasms